<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00680771</url>
  </required_header>
  <id_info>
    <org_study_id>RSRB # 19132</org_study_id>
    <secondary_id>1K23NR010408</secondary_id>
    <nct_id>NCT00680771</nct_id>
  </id_info>
  <brief_title>The Psychoneuroimmunology of Insomnia</brief_title>
  <official_title>The Psychoneuroimmunology of Insomnia: Response to a Vaccine Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Nursing Research (NINR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic insomnia affects approximately 8-9% of the population. The prevalence of this
      disorder rises dramatically across the lifespan, especially so in women. When it is chronic,
      insomnia is associated with increased fatigue, cognitive impairment, mood disturbance,
      physical complaints, diminished quality of life and increased health care consumption. There
      is also more limited evidence (based on epidemiologic studies or experimental studies in
      healthy subjects) that insomnia and/or sleep loss may be a risk factor for hypertension
      and/or cardiovascular disease and increased mortality.

      Despite its prevalence and consequences, the pathophysiology of insomnia and, specifically,
      the pathway by which morbidity risk is conferred, has been relatively unstudied. With respect
      to medical illness in particular, insomnia may confer risk in several ways, including: 1) an
      inherent compromise in the restorative/conservative function of sleep, 2) the deleterious
      effects of &quot;hyperarousal&quot; and/or HPA axis abnormalities on end organ integrity and function,
      and/or 3) diminished immunocompetence. This study focuses on the last of these possibilities,
      the relationship between immune function and sleep.

      The study compares immune response to a vaccine challenge in two groups: good sleepers and
      patients with chronic insomnia. The primary study hypothesis is that the insomnia group will
      have a decreased rate of adaptive immune response to the vaccine challenge than that of the
      good sleeper group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Positive Antibody Response</measure>
    <time_frame>3 Months after initial vaccination</time_frame>
    <description>Sero-Response to the Hepatitis B vaccine, defined as reaching or exceeding a Hepatitis B surface antigen level of greater than or equal to 10mIU/mL.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">28</enrollment>
  <condition>Primary Insomnia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Primary Insomnia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Good Sleepers</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Community Sample
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Their sleep schedule will include a typical bedtime of between 9:00 p.m. and 12:00 a.m. to
        minimize circadian rhythm influences on the diagnoses of Primary Insomnia (PI).

        PIs will also meet the sleep disturbance criteria of the Pittsburgh Sleep Quality
        Index(PSQI) &gt; 5 and the Insomnia Severity Index (ISI)&gt; 15 and one of the following minimal
        characteristics both at intake and as an average profile from the two weeks of baseline
        diaries: &gt; 30 min. sleep-onset latency (SL), &gt; 30 min. of wake after sleep-onset (WASO),
        Early Morning Awakening &gt;30 min. prior to the desired wake up time, or any two of the above
        complaints (Mixed Insomnia); Total Sleep Time (TST) &lt; 6 hours [unless the Sleep Efficiency
        is &lt; 80%] and the problem frequency must be &gt; 3 nights/week; problem duration &gt; 6 months.

        Good Sleeper participants will report that they obtain enough sleep and that their sleep is
        restorative with average SL and WASO &lt; 15 minutes, TST &gt; 6 hours ESS &lt; 5 on the ESS, &lt; 5 on
        the PSQI, and &lt; 7 on the ISI.

        Exclusion Criteria for All Subjects

          -  any conditions contraindicated by the vaccine manufacturer or any history of allergic
             reactions to vaccines

          -  Undergoing and/or taking immunosuppressive therapies

          -  Sero-positive for Hep B antibodies

          -  Inadequate language comprehension

          -  Menopause, peri-menopause or premenstrual syndrome

          -  Pregnancy

          -  Unstable medical or psychiatric illness

          -  History of head injury with a sustained loss of consciousness

          -  Evidence of active illicit substance use or fitting criteria for alcohol abuse or
             dependence

          -  Use of medications thought to alter sleep such as stimulants, sedating
             antidepressants, and hypnotics

          -  Symptoms suggestive of sleep disorders other than Insomnia

          -  Polysomnographic data indicating sleep disorders other than Insomnia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilfred R Pigeon, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester Sleep Research Laboratory</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2008</study_first_submitted>
  <study_first_submitted_qc>May 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2008</study_first_posted>
  <results_first_submitted>September 26, 2011</results_first_submitted>
  <results_first_submitted_qc>September 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 17, 2012</results_first_posted>
  <last_update_submitted>September 14, 2012</last_update_submitted>
  <last_update_submitted_qc>September 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Wilfred Pigeon</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Primary Insomnia</keyword>
  <keyword>Insomnia</keyword>
  <keyword>Good Sleepers</keyword>
  <keyword>Hep B</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Pre-menopausal women aged 25-50 with either Primary Insomnia (PI) or Good Sleep (GS) were recruited from posters, flyers, and newspaper advertisements in the Rochester, NY region during the period of 2008-2010.</recruitment_details>
      <pre_assignment_details>There were two study groups, but this did not involve random assignment. Group assignment to either Primary Insomnia or Good Sleeper was based on subjective (sleep diaries and validated instruments)and objective (polysomnography) measures of sleep. Twenty-eight subjects were enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Primary Insomnia</title>
          <description>Subjects meeting criteria for primary insomnia.</description>
        </group>
        <group group_id="P2">
          <title>Good Sleepers</title>
          <description>Subjects meeting criteira for Good Sleepers</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sleep Apnea suspected after PSG</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prior Exposure to Hepatitus B Vaccine</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Primary Insomnia</title>
          <description>patients meeting criteria for primary insomnia.</description>
        </group>
        <group group_id="B2">
          <title>Good Sleepers</title>
          <description>participants meetoing criteira for Good Sleepers</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Positive Antibody Response</title>
        <description>Sero-Response to the Hepatitis B vaccine, defined as reaching or exceeding a Hepatitis B surface antigen level of greater than or equal to 10mIU/mL.</description>
        <time_frame>3 Months after initial vaccination</time_frame>
        <population>From subjects with complete data only.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Insomnia</title>
            <description>patients meeting criteria for primary insomnia.</description>
          </group>
          <group group_id="O2">
            <title>Good Sleepers</title>
            <description>participants meetoing criteira for Good Sleepers</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Antibody Response</title>
          <description>Sero-Response to the Hepatitis B vaccine, defined as reaching or exceeding a Hepatitis B surface antigen level of greater than or equal to 10mIU/mL.</description>
          <population>From subjects with complete data only.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Primary Insomnia</title>
          <description>patients meeting criteria for primary insomnia.</description>
        </group>
        <group group_id="E2">
          <title>Good Sleepers</title>
          <description>participants meetoing criteira for Good Sleepers</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sample size limited by much higher than expected number of otherwise eligible participants having alrady been exposed to Hep B vaccine or virus.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Wilfred Pigeon</name_or_title>
      <organization>University of rochester</organization>
      <phone>(585) 275-3374</phone>
      <email>Wilfred_pigeon@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

